# Wuxi Kejin Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuxi-kejin-biotechnology-co

- Industry: Biotechnology
- Headquarters: Wuxi, China
- Total disclosed funding: $16M
- Latest round: Angel (Feb 28, 2022)
- Investors on record: 3

## About

Based in Wuxi, China, and founded in 2022, Wuxi Kejin Biotechnology Co., Ltd is a biotechnology company that focuses on the research, development and production of anticancer drugs. The company's founder and CEO, Dr. Haifeng Wang, was in charge of market development in the Wuxi App Tec. The company's co-founder and Chief Scientific Officer, Prof. Jose Carlos Segovia, also works at the CIEMAT in Spain. He has applied for five orphan drugs.

The company has the gene editing technology platform CRISPR 2.0. Combines with the AAV (adeno-associated viral vector) delivery system, the gene editing efficiency can reach 70%. It can also avoid the risk of CRISPR off-target and various immunological and oncogenic risks of AAV entering the body. The company is working on the development of cellular therapeutics for pyruvate kinase deficiency (PKD) and other rare diseases of the blood. The PKD pipeline is expected to complete IND filings in China and Europe in 2023.

## Funding rounds

- Angel, Feb 28, 2022, $16M — GP Capital, MED-FINE Capital, Jinkong Qiyuan Capital

## Investors

- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Angel
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Angel
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Angel